Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;108(3):385-93.
doi: 10.1007/s11060-012-0841-4. Epub 2012 Mar 2.

t-AUCB, an improved sEH inhibitor, suppresses human glioblastoma cell growth by activating NF-κB-p65

Junyang Li  1 , Hongyi Liu, Biao Xing, Yanzhe Yu, Hui Wang, Gong Chen, Bing Gu, Guofeng Zhang, Dong Wei, Peiyuan Gu, Meng Li, Weixing Hu
Affiliations

t-AUCB, an improved sEH inhibitor, suppresses human glioblastoma cell growth by activating NF-κB-p65

Junyang Li et al. J Neurooncol. 2012 Jul.

Abstract

Although sEH inhibitors are well studied in inflammatory and cardiovascular diseases, their effects on gliomas are unclear. In this study, we investigated the effects of t-AUCB, a more potent and selective sEH inhibitor, on U251 and U87 human glioblastoma cell lines and the HepG2 human hepatocellular carcinoma cell line. Our results showed that t-AUCB efficiently inhibited sEH activities in all three cell lines (the inhibition rate was more than 80% in each) and suppressed U251 and U87 cell growth in a dose-dependent manner, but exhibited no cell growth inhibition on HepG2. We detected high levels of phosphorylated NF-κB-p65 (Ser536) in t-AUCB-treated U251 and U87 cells, and then found that the NF-κB inhibitor PDTC can completely abolish t-AUCB-induced growth inhibition. This indicated that t-AUCB suppresses U251 and U87 cell growth by activating NF-κB-p65. Moreover, we found that t-AUCB induces cell-cycle G0/G1 phase arrest by regulating Cyclin D1 mRNA and protein levels and CDC2 (Thr161) phosphorylation level. We propose to further test this promising reagent for its anti-glioma activity in clinical relevant orthotopic brain glioma models.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. FASEB J. 2011 Feb;25(2):703-13 - PubMed
    1. Biochem Pharmacol. 2010 Mar 15;79(6):880-7 - PubMed
    1. J Neurooncol. 2010 Feb;96(3):349-57 - PubMed
    1. Anal Bioanal Chem. 2011 May;400(5):1359-66 - PubMed
    1. Biochem Soc Trans. 2010 Feb;38(Pt 1):217-22 - PubMed

Publication types

MeSH terms

LinkOut - more resources